A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
Yuguo Liu, Lijuan Luan, Xingli Wang Department of Gastrointestinal Surgery, Shandong Tumor Hospital, Jinan, Shandong Province, People’s Republic of China Background: This study investigated the efficacy and safety of a new treatment strategy of combining panitumumab and bevacizumab, plus...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-05-01
|
| Series: | OncoTargets and Therapy |
| Online Access: | http://www.dovepress.com/a-randomized-phase-ii-clinical-study-of-combining-panitumumab-and-beva-peer-reviewed-article-OTT |